.Nature Medication, Published online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized stage 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) procedure of people with HER2+ advanced breast cancer cells as well as energetic or dependable mind metastases showed regular intracranial activity as well as systemic effectiveness of T-DXd.